| |
|
|
|
CfPA-The Center for Professional Advancement, New Brunswick, NJ or Virtually
July 29-31, 2019
Who Should Attend?
This course is intended for professionals who participate in, or are responsible for, non-clinical safety assessment in small or large corporations in the pharmaceutical or biopharmaceutical industries. It is orientated particularly toward those with relatively limited development experience, but offers benefit to other members or representatives on drug-development project teams and their managers, especially:
• Non-clinical safety scientists including toxicologists and toxicologic
pathologists
• Toxicokineticists
• Regulatory affairs personnel
• Project managers Course Description
|
|
|
|
|
|
|
|
Organized by:
|
|
CfPA-The Center for Professional Advancement |
|
|
Invited Speakers:
|
|
 Dr. Stephen J. Newsholme, Drug Development Consultant |
Stephen J. Newsholme, currently a freelance drug-development consultant, has 30 years of experience in a large pharmaceutical company as a pathologist and director of non-clinical safety. This has provided him a deep and broad knowledge of drug development, particularly at the early end, and he has participated in selecting many new drug candidate molecules and in the planning, preparation, review and submission of numerous INDs and CTAs. He has steered early-stage development teams and trained and mentored many development team members. He has also designed and delivered drug-development courses to team representatives across multiple functional groups.
Dr. Newsholme’s experience is international in scope: He holds degrees in physiology and veterinary medicine from the University of London and a pathology degree from the University of Pretoria as well as being a Diplomate of the American College of Veterinary Pathologists. He has also chaired international, multidisciplinary research teams to investigate and resolve drug safety issues. He is a member of the American College of Veterinary Pathologists, Society of Toxicologic Pathologists, American Society for Investigative Pathology, the Royal College of Veterinary Surgeons and the Roundtable of Toxicology Consultants, and is a former member of ILSI/HESI where he chaired the Emerging Issues Committee. He has authored or co-authored more than 50 publications relating to pathology, toxicology and safety assessment.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
Please click here for registration information.
|
|
|
E-mail:
|
|
Jmorbit@cfpa.com
|
|
|
|
|
|
|
|
|
Participants are encouraged to bring their questions and problems to the course which can be included as part of the discussions.